Chilean health regulator approves CanSino COVID-19 vaccine for emergency use




  • In Business
  • 2021-04-07 23:31:28Z
  • By Reuters
 

By Fabian Cambero

SANTIAGO (Reuters) - Chile's health regulator on Wednesday approved emergency use of the COVID-19 vaccine developed by Chinese company CanSino, as the South American country forges ahead with a massive vaccination campaign and fights a second spike of cases.

Chile hosted a late-stage trial for the CanSino vaccine and President Sebastian Pinera said at the end of March that he had signed a deal to buy 1.8 million vials of the single-dose vaccine.

The vaccine, which has received similar approval in China, Mexico, Pakistan and Hungary, is due to arrive in May and June, the presidency said, and could help inoculate the country's more rural populations since it only requires one injection.

Johnson & Johnson's one-dose vaccine also had a trial in Chile, but a long-promised deal for the supply has failed to materialize due to demand for the drug from the United States and Europe.

The Institute of Public Health (ISP) approved CanSino's emergency roll-out by 10 votes in favor, two against and one abstention, for people up to the age of 60.

Chile has so far inoculated 7.1 million people with one dose of either the Sinovac or Pfizer BioNTech vaccines and 4.2 mln with two doses. It aims to vaccinate nine million people with at least one dose by May 9 and 80% of its target population by July.

The country is at present in the grip of the worst outbreak so far of the virus, hitting a peak of more than 8,000 cases last week.

Health experts have blamed the end of the southern hemisphere summer holidays and the return of the active population to work, school and public transport for the second wave, along with a relaxation of self-care measures and movement restrictions.

(Reporting by Aislinn Laing; Editing by David Gregorio)

COMMENTS

More Related News

U.S. FDA finds peeling paint, debris at U.S. plant making J&J
U.S. FDA finds peeling paint, debris at U.S. plant making J&J's COVID-19 vaccine
  • US
  • 2021-04-21 14:07:25Z

Emergent Biosolutions, which owns the plant, has been seeking regulatory authorization to make the J&J vaccine there. It stopped production at the plant...

J&J to cooperate in study of rare clots linked to COVID-19 vaccine, German scientist says
J&J to cooperate in study of rare clots linked to COVID-19 vaccine, German scientist says
  • US
  • 2021-04-20 19:44:08Z

A German scientist studying extremely rare blood clots linked to AstraZeneca's COVID-19 vaccine said on Tuesday Johnson & Johnson has agreed to work with him...

EU regulator finds possible link between J&J COVID-19 vaccine and blood clots
EU regulator finds possible link between J&J COVID-19 vaccine and blood clots
  • US
  • 2021-04-20 14:23:40Z

The European Medicines Agency (EMA) said on Tuesday its safety committee had concluded that a warning about unusual blood clots with low platelets must be...

J&J seeks approval to conduct local trial of its COVID-19 vaccine in India
J&J seeks approval to conduct local trial of its COVID-19 vaccine in India
  • US
  • 2021-04-20 10:42:06Z

BENGALURU (Reuters) -Johnson & Johnson is seeking to conduct a local clinical trial in India for its single-dose COVID-19 vaccine, which was paused in the...

J&J reports $100 million in vaccine sales as results top forecasts
J&J reports $100 million in vaccine sales as results top forecasts
  • US
  • 2021-04-20 10:37:14Z

The company, which has previously said the vaccine will be available on a not-for-profit basis until the end of the pandemic, also tightened its forecast for...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Business